Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.

Journal of thrombosis and thrombolysis - 1 Nov 2020

Levraut Michaël, Legros Laurence, Drappier Charles, Béné Marie C, Queyrel Viviane, Raynaud Sophie, Martis Nihal

Abstract excerpt

To determine the prevalence of the V617F Janus Kinase 2 (JAK2) mutation in patients with thrombosis without other biological signs of underlying myeloproliferative neoplasm (MPN) and identify associated risk factors for thrombosis. Over a 10-year period, data were collected from patients with thrombotic events and who had also been screened for the V617F JAK2 mutation. Patients with signs of underlying MPN, such...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to C-Reactive Protein
Share to Intracranial Thrombosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Platelet Count

Share to Splenomegaly

Share to Thrombosis

Share to Venous Thrombosis

Source

Identifiers

PMID: 32266587
DOI: 10.1007/s11239-020-02100-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.PMID 32266587Read ↗

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.Semantic proximity Read ↗

JAK2V617F mutation in patients with thrombosis: to screen or not to screen?Semantic proximity Read ↗

JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis.Semantic proximity Read ↗

Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.Semantic proximity Read ↗

JAK2 mutations across a spectrum of venous thrombosis cases.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?Semantic proximity Read ↗

[Thrombosis in myeloproliferative neoplasms].Semantic proximity Read ↗

Splanchnic vein thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Semantic proximity Read ↗

JAK2 mutation and thrombosis in the myeloproliferative neoplasms.Semantic proximity Read ↗

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.